Hypoparathyroidism future or investigational therapies
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]
Overview
In 1996, Winer and collegues demonstrated a reduction in calcium excretion in patients of hypoparathyroidism when treated with PTH 1-34 (teriparatide) when compared with treatment with calcitriol and calcium. PTH 1–34 (teriparatide) twice daily administered subcutaneoulsy provides a safe and effective alternative to calcitriol therapy and is capable of maintaining normocalcemia without hypercalciuria for at least 3 yr in patients with hypoparathyroidism. PTH 1-34 (teriparatide) has shown to improve the mental and physical health in hypoparathyroid patients.
Future or Investigational Therapies
Parathyroid hormone 1-34 (teriparatide)
- In 1996, Winer and collegues demonstrated a reduction in calcium excretion in patients of hypoparathyroidism when treated with PTH 1-34 (teriparatide) when compared with treatment with calcitriol and calcium.[1]
- Synthetic human was approved as a treatment for severe osteoporosis in 2002.
- PTH 1–34 (teriparatide) twice-daily shown to provide effective treatment of hypoparathyroidism and reduces the fluctuation in serum calcium levels at a lower total daily parathyroid hormone dose when compared to once daily regimen.[2]
- PTH 1–34 (teriparatide) twice daily administered subcutaneoulsy provides a safe and effective alternative to calcitriol therapy and is capable of maintaining normocalcemia without hypercalciuria for at least 3 yr in patients with hypoparathyroidism.[3]
- PTH 1–34 (teriparatide) is also safe and effective for treatment children with hypoparathyroidism when compared with conventional therapy.[4]
- PTH 1–34 (teriparatide) has shown to improve the mental and physical health in hypoparathyroid patients.[5]
References
- ↑ Winer KK, Yanovski JA, Cutler GB (1996). “Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism”. JAMA. 276 (8): 631–6. PMID 8773636.
- ↑ Winer KK, Yanovski JA, Sarani B, Cutler GB (1998). “A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism”. J. Clin. Endocrinol. Metab. 83 (10): 3480–6. doi:10.1210/jcem.83.10.5185. PMID 9768650.
- ↑ Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB (2003). “Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium”. J. Clin. Endocrinol. Metab. 88 (9): 4214–20. doi:10.1210/jc.2002-021736. PMID 12970289.
- ↑ Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB (2010). “Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium”. J. Clin. Endocrinol. Metab. 95 (6): 2680–8. doi:10.1210/jc.2009-2464. PMC 2902068. PMID 20392870.
- ↑ Santonati A, Palermo A, Maddaloni E, Bosco D, Spada A, Grimaldi F, Raggiunti B, Volpe R, Manfrini S, Vescini F (2015). “PTH(1-34) for Surgical Hypoparathyroidism: A Prospective, Open-Label Investigation of Efficacy and Quality of Life”. J. Clin. Endocrinol. Metab. 100 (9): 3590–7. doi:10.1210/jc.2015-1855. PMID 26196949.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH